


Finding new anticancer drugs


Novel HT-screening methodology for simultaneous identification of different classes of molecules

Biotech and Health Care


The principle



The methodology



The application



Value proposition/USP

Screening methods for the identification of novel chemotherapeutic drugs are either too unspecific (for instance plain cell viability) or too specific, relying on the development of a specific assay for a specific target. Here we present a methodology that allows the simultaneous identification of molecules belonging to different types therapeutic targets in one single assay. This method is based on the multi-parameter analysis of replication stress markers, aiming at discovering new classes of successful chemotherapeutic drugs and novel compounds that kill cancer cells by replication stress.

Business Opportunity/Objective/commercial perspectives

The team behind the invention is working towards a spin out company and the institutions will offer the company an exclusive license to this invention and follow up inventions. The spin out company are looking for potential investors and/or partners that can support them in bringing the technology on the market.

Technology description/technology Summary

The screening method uses a cell-based assay to depict the response elicited by the drug of interest in cancer cells, which is read by automated microscopy and processed by image analysis. The result is a multi-dimensional quantitative profile of replication stress markers, which derives a unique signature for each type of molecule. These signatures can be used to identify different classes of molecules with extreme accuracy, and the assay also depicts novel stress responses that can lead to the development of new targets.

Development phase/current state

The methodology has successfully been tested in a small setting and is ready to be applied at large scale.

The inventors

Jiri Lukas (Prof, UCPH)
Luis Toledo (Associate Prof, UCPH)

Contact information

Bo Stenhuus (Commercial Officer)
Bo.stenhuus@adm.ku.dk
+45 2961 1382

The invention is protected in **WO2016078670**